Healthy Subjects Clinical Trial
— FruEx2Official title:
Effects of Exercise on Fructose Metabolism
Verified date | June 2014 |
Source | University of Lausanne |
Contact | n/a |
Is FDA regulated | No |
Health authority | Switzerland: Ethikkommission |
Study type | Interventional |
A high fructose diet increases fasting and post-prandial triglyceride (TG) concentrations in
sedentary healthy human subjects.These effects may be secondary to fructose-induced hepatic
de novo lipogenesis. Recent evidence indicate that exercise can prevent fructose induced
dyslipidemia.This study will evaluate
1. how exercise effects the metabolic fate of oral fructose 1a) when exercise is performed
before fructose ingestion 1b) when exercise is performed after fructose ingestion
Metabolic effects of exercise will be assessed in healthy male subjects by measuring
fructose oxidation (13CO2 production), fructose conversion into glucose (13C glucose
concentrations in blood) and hepatic fructose conversion into lipid (13C palmitate-very
low density lipoprotein (VLDL) concentrations in blood) after ingestion of 13C-labelled
fructose meals
2. how fructose and protein modulate muscle glycogen and intramyocellular lipid repletion
after exercise Healthy male subjects will be fed various fructose, glucose, lipid and
whey protein meals after a glycogen/intramyocellular lipid depleting exercise. The
effects of meals' composition will be assessed after 24 hours by measuring
intramyocellular lipids and glycogen using proton-magnetic resonance spectroscopy
(MRS).
Status | Completed |
Enrollment | 8 |
Est. completion date | January 2014 |
Est. primary completion date | January 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 40 Years |
Eligibility |
Inclusion Criteria: - males - 18-40 years old - 19 kg/m2>BMI>25kg/m2 - moderate to high usual physical activity - non-smokers Exclusion Criteria: - family history of diabetes mellitus - ECG anomaly - any medication - participation to blood spending or other clinical study in the 3 months before the beginning of this study - consumption of drugs - consumption of more than 50g alcool/week - family history of food intolerance |
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science
Country | Name | City | State |
---|---|---|---|
Switzerland | Centre Hospitalier Universitaire Vaudois | Lausanne | Vaud |
Lead Sponsor | Collaborator |
---|---|
University of Lausanne | Centre Hospitalier Universitaire Vaudois, University of Bern |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Plasma triglyceride | measurement of total and VLDL-TG concentrations in study 1 | measurements in fasting conditions and every hour from 7:00 am to 4:00 pm (up to 9 hours) | No |
Primary | intramyocellular lipids | Measurement by 1H-MRS in muscle vastus lateralis in study 2 | after glycogen/intramyocellular lipid depleting exercise and after 24 hour controlled feeding post exercise | No |
Primary | Fructose conversion into lipids | Estimated from 13C palmitate-VLDL concentration | measured from 7:00 am to 4:00 pm in study 1 (up to 9 hours) | No |
Secondary | Fructose conversion into glucose | measurements obtained from plasma 13C glucose concentrations and whole body glucose production measured by 6,6 d2 glucose in study 1) | measured between 7:00 am and 4:oo pm (up to 9 hours) | No |
Secondary | intramyocellular glycogen concentrations | Measured by 1H-MRS in muscle vastus lateralis in study 2 | after glycogen/intramyocellular lipid depleting exercise and after 24 hour controlled feeding post exercise | No |
Secondary | fructose oxidation | Calculated from breath 13CO2 production | measured from 7:00 am to 4:00 pm in study 1 (up to 9 hours) | No |
Secondary | exogenous lipid oxidation | Lipids ingested will be labeled with 13C-triolein, and exogenous lipid oxidation will be measured from breath 13CO2 production | measured from 7:00 am to 4:00 pm in study 2 (up to 9 hours) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05483998 -
A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT02417714 -
Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
|
||
Recruiting |
NCT02235012 -
Cognitive Biases Under Ketamine
|
N/A | |
Completed |
NCT04418973 -
Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject.
|
N/A | |
Completed |
NCT05088343 -
Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06248801 -
Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets
|
Phase 1 | |
Terminated |
NCT04068259 -
Single Ascending Dose Study of PBI-4547 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03279302 -
Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06233162 -
Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets
|
Phase 1 | |
Recruiting |
NCT04159844 -
Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects
|
N/A | |
Completed |
NCT06137911 -
Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults.
|
Phase 1 | |
Completed |
NCT04849286 -
Measurement of HTL0016878 in Cerebrospinal Fluid
|
Phase 1 | |
Not yet recruiting |
NCT06233227 -
Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule
|
Phase 1 | |
Completed |
NCT04096157 -
A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants
|
Phase 1 | |
Completed |
NCT01200368 -
Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants
|
Phase 3 | |
Recruiting |
NCT05805033 -
Peri-Implant Soft Tissue Integration in Humans: Influence of Material
|
N/A | |
Completed |
NCT04027803 -
Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®
|
Phase 1 | |
Recruiting |
NCT03467880 -
Multicenter Study of Impulse Oscillometry in Chinese
|
N/A | |
Completed |
NCT02903095 -
Single Ascending Dose Study of TD-1439 in Healthy Subjects
|
Phase 1 | |
Active, not recruiting |
NCT02341508 -
A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers
|
Phase 1 |